Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

How To Label A Biosimilar? Copy The Reference Product, FDA Told Sandoz

Executive Summary

But agency had to weigh how presentation differences between Sandoz’s Zarxio and Amgen’s Neupogen, as well as Neupogen-specific safety information, should be reflected in the biosimilar’s labeling.


Related Content

FDA Biosimilar Policy Continues To Evolve With Approval Of Sandoz Erelzi
Behind The Approval Letter: Drug Review Profiles
Zarxio Syringe’s Limitations May Delay Decision On Neupogen Interchangeability
Sorry, Wrong Email: FDA’s ‘Oops’ Moment In The Zarxio Review
Zarxio Reviewers
FDA’s Inaugural Biosimilar Review Bumpier Than First Appeared
Zarxio Clinical Development Timeline
Sandoz’s Biosimilar Data-Bridging Plans For Zarxio Faced FDA Doubts
Biosimilar Guidances: Broader Populations Permitted; More Immunogenicity Requested
Biosimilar But Different: Zarxio, Neupogen Diverge On Syringes, Vials


Related Companies